Navigation Links
American Oriental Bioengineering Reports Second Quarter 2009 Financial Results
Date:8/7/2009

NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ --


            --2Q09 Revenue Increased 20.7% YoY to $71.2 Million--

--2Q09 Net Income Attributable to Controlling Interest was $13.2 million or

                          $0.17 per Diluted Share--

   -- Company Generates Approximately $22.9 Million of Operating Cashflow--

American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced financial results for the second quarter ended June 30, 2009.

Revenue in the second quarter of 2009 increased 20.7% to $71.2 million from $59.0 million in the second quarter of 2008, reflecting continued demand for the Company's core pharmaceutical and nutraceutical products. Revenue from pharmaceutical products increased 17.4% to $58.4 million from $49.8 million in the prior year's second quarter. Revenue from prescription pharmaceutical products increased 23.2% to $25.2 million during the second quarter of 2009, reflecting an increase in sales from prescription formulation Jinji and CCXA products, which offset declines in sales of Shuanghuanglian Injection Powder ("SHL"). OTC pharmaceutical products generated $33.3 million in revenue during the second quarter of 2009, up from $29.4 million in the prior year's period, reflecting continued demand for Boke and GLP products, as a result of marketing efforts and improved recognition of the products. Nutraceutical products generated revenue of approximately $9.5 million in the second quarter of 2009, up 3.3% from $9.2 million in the prior year's period, reflecting increased sales of new beverage products launched in the beginning of 2009. The Company generated $3.3 million from its distribution business.

Gross profit in the second quarter of 2009 increased 3.9% to $41.6 million from $40.1 million in the second quarter of 2008. Gross margin was 58.4%, compared to 67.9% in the prior year's period, reflecting continued revenue mix shift to CCXA's generic product sales, increasing raw material prices and low margin distribution business.

Operating income in the second quarter of 2009 was $18.3 million compared to $18.7 million in the second quarter of 2008. Selling and marketing expenses increased 22.2% to $9.4 million from $7.7 million in the prior year period. The increase primarily reflects marketing and promotional initiatives to support the continuous growth of revenues. Advertising expense was $7.8 million in the second quarter of 2009, compared to $7.5 million in the prior year's period.

Net income attributable to controlling interest for the second quarter of 2009 was $13.2 million, compared to $13.9 million in the prior year's period. Excluding $1.4 million of interest expense and $0.2 million of amortized financing costs related to the Company's outstanding convertible notes, the Company's net income attributable to controlling interest increased 6.5% to $14.8 million, or $0.17 per diluted share. In the prior year's second quarter, net income per diluted share was approximately $0.18.

As of June 30, 2009, the Company had $100.7 million in cash and generated approximately $22.9 million of operating cashflow during the second quarter of 2009.

Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are pleased with our second quarter performance as we continued to enhance our diversified product portfolio and pursue further vertical integration. Our marketing capabilities, extensive distribution platform, diversified product offering and ongoing rural expansion offset anticipated challenges in SHL sales during the second quarter of 2009. We also made significant progress this quarter optimizing our distribution business, so that we solidify our presence in Tier I and II hospital channels and remain on-track for net income contributions for the full year. We continue to drive revenue growth and consistently generate cash despite the uncertain regulatory environment in China's healthcare sector, and we are confident in our ability to be a top-five pharmaceutical company in China."

Conference Call

The Company will hold a conference call at 8:00 am ET on August 7, 2009 to discuss second quarter 2009 results. Listeners may access the call by dialing 1-866-761-0749 or 1-617-614-2707 for international callers, access code: 54060064. A webcast will also be available through AOB's website at http://www.bioaobo.com . A replay of the call will be available through August 14, 2009. Listeners may access the replay by dialing 1-888-286-8010 or 1-617-801-6888 for international callers, access code: 18519426.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.



           AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
                    CONDENSED CONSOLIDATED BALANCE SHEETS

                    ASSETS

                                                 JUNE 30,         DECEMBER 31,
                                                   2009              2008
                                                (UNAUDITED)
    CURRENT ASSETS
    Cash and cash equivalents                  $100,730,402       $70,636,510
    Accounts receivable, net of reserve of
     $505,433 and $226,330 at June 30, 2009
     and December 31, 2008, respectively         31,396,881        36,982,167
    Inventories, net                             16,829,834        13,042,123
    Advances to suppliers                         3,135,694         3,593,979
    Notes receivable                                 81,075           708,076
    Refundable deposit                                   --         6,396,996
    Deferred tax assets                             421,660           347,216
    Other current assets                            937,087           744,903
    Total Current Assets                        153,532,633       132,451,970

    LONG-TERM ASSETS
    Property, plant and equipment, net           96,151,689        98,154,443
    Land use rights, net                        148,301,203       148,988,870
    Deposit for long-term assets                  6,717,514         6,347,174
    Construction in progress                     25,871,656        25,385,835
    Deferred tax assets                           1,327,627         1,313,832
    Other intangible assets, net                 21,146,928        23,690,440
    Goodwill                                     28,543,226        28,543,226
    Long-term investment and advance             55,452,267        54,963,064
    Unamortized financing cost                    3,751,838         4,215,983
    Total Long-Term Assets                      387,263,948       391,602,867

    TOTAL ASSETS                               $540,796,581      $524,054,837

            LIABILITIES AND EQUITY

                                                 JUNE 30,         DECEMBER 31,
                                                   2009              2008
                                                (UNAUDITED)
    CURRENT LIABILITIES
    Accounts payable                            $12,548,451       $12,287,887
    Notes payables                                3,011,486         3,262,877
    Other payables and accrued expenses          14,251,673        19,766,652
    Taxes payable                                   625,261           420,671
    Short-term bank loans                         6,720,430         7,140,148
    Current portion of long-term bank loans          59,396            58,659
    Other liabilities                             2,511,295         2,253,440
    Deferred tax liability                        1,121,738           846,026
    Total Current Liabilities                    40,849,730        46,036,360

    LONG-TERM LIABILITIES
    Long-term bank loans, net of current
     portion                                        774,641           804,521
    Long-term notes payable                              --           269,908
    Deferred tax liabilities                     15,963,766        16,083,768
    Convertible notes                           115,000,000       115,000,000
    Total Long-Term Liabilities                 131,738,407       132,158,197
    TOTAL LIABILITIES                           172,588,137       178,194,557

    COMMITMENTS

    EQUITY
    SHAREHOLDERS' EQUITY
    Preferred stock, $0.001 par value;
     2,000,000 shares authorized;
     1,000,000 shares issued and
     outstanding at June 30, 2009 and
     December 31, 2008, respectively                  1,000             1,000
    Common stock, $0.001 par value;
     150,000,000 shares authorized;
     78,301,439 and 78,249,264 shares
     issued and outstanding at June 30,
     2009 and December 31, 2008, respectively        78,301            78,249
    Common stock to be issued                       311,999           376,335
    Prepaid forward repurchase contract         (29,998,616)      (29,998,616)
    Additional paid-in capital                  196,752,860       195,741,544
    Retained earnings (the restricted
     portion of retained earnings is
     $29,532,699 at June 30, 2009 and
     December 31, 2008, respectively)           171,019,548       149,923,681
    Accumulated other comprehensive income       29,510,788        29,086,006
    Total Shareholders' Equity                  367,675,880       345,208,199
    NON-CONTROLLING INTEREST                        532,564           652,081
    TOTAL EQUITY                                368,208,444       345,860,280
    TOTAL LIABILITIES AND EQUITY               $540,796,581      $524,054,837



           AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES
     CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
                                 (UNAUDITED)

                             THREE MONTHS ENDED         SIX MONTHS ENDED
                                  JUNE 30,                  JUNE 30,
                             2009         2008          2009         2008

    REVENUES              $71,222,037  $59,010,005  $117,299,227  $97,778,603
    COST OF GOODS SOLD     29,594,923   18,928,447    47,255,261   31,406,083
    GROSS PROFIT           41,627,114   40,081,558    70,043,966   66,372,520

        Selling and
         marketing          9,396,129    7,687,892    14,607,631   12,717,600
        Advertising         7,779,936    7,452,231    13,347,293   11,846,572
        General and
         administrative     4,315,714    5,253,274     8,881,357    9,165,957
        Depreciation and
         amortization       1,850,274    1,010,461     3,709,189    1,987,671
        Total operating
         expenses          23,342,053   21,403,858    40,545,470   35,717,800

    INCOME FROM
     OPERATIONS            18,285,061   18,677,700    29,498,496   30,654,720

    EQUITY IN EARNINGS
     (LOSS) FROM
     UNCONSOLIDATED
     ENTITIES                (173,258)    (640,008)      264,536     (641,067)
    INTEREST INCOME
     (EXPENSE), NET        (1,620,069)     (30,616)   (3,199,338)     (13,769)
    OTHER INCOME
     (EXPENSE), NET           (16,329)    (255,770)     (114,938)    (356,502)
    INCOME BEFORE INCOME
     TAXES                 16,475,405   17,751,306    26,448,756   29,643,382

    INCOME TAXES            3,369,107    3,891,614     5,472,406    6,361,562

    NET INCOME             13,106,298   13,859,692    20,976,350   23,281,820
    NET INCOME
     ATTRIBUTABLE TO NON-
     CONTROLLING INTEREST     123,068           --       119,517           --
    NET INCOME
     ATTRIBUTABLE TO
     CONTROLLING INTEREST  13,229,366   13,859,692    21,095,867   23,281,820

    OTHER COMPREHENSIVE
     INCOME
        Foreign currency
         translation gain,
         net of tax            46,316    5,154,761       424,782   12,089,196
    TOTAL OTHER
     COMPREHENSIVE
     INCOME, NET OF TAX        46,316    5,154,761       424,782   12,089,196

    COMPREHENSIVE INCOME  $13,275,682  $19,014,453   $21,520,649  $35,371,016

    NET INCOME PER SHARE
        BASIC                   $0.18        $0.18         $0.28        $0.30
        DILUTED                 $0.17        $0.18         $0.28        $0.30

    WEIGHTED AVERAGE
     NUMBER OF SHARES
     OUTSTANDING
        BASIC              74,582,920   78,223,659    74,560,809   78,207,405
        DILUTED            88,815,593   78,223,659    86,939,711   78,208,181


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):